PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143378
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143378
APOE Genotype Test market size was valued at US$ 801.7 Million in 2025, expanding at a CAGR of 10.2% from 2026 to 2033.
The APOE genotyping is a genetic test that uses the DNA to find out the type of apolipoprotein E gene that an individual has, making it possible for doctors to predict any risks of neurodegenerative and lipid diseases that may be transmitted through generations. The process involves the initial stage of the extraction of pure gDNA from blood or saliva samples and then proceeds with a targeted PCR of the most informative polymorphic loci of the gene, either followed by a discrimination procedure based on the real-time fluorescence probe technology or the one based on the RFLP technology, with the final stage of generating a report in the specified format, where three possible results (ε2/ε3/ε4) are interpreted into risk categories. It thereby provides a reliable framework for identifying APOE variants and supporting personalised clinical risk assessment.
APOE Genotype Test Market- Market Dynamics
Rising Alzheimer's Disease Prevalence To Drive Market Demand
The rising prevalence of Alzheimer's disease is expected to drive the APOE Genotype Test market forward. APOE genotype testing helps identify any genetic mutations that increase the chances of Alzheimer's disease. Since the number of people diagnosed with Alzheimer's disease has been increasing, the demand for genetic testing is expected to rise in the coming years. For example, as per data published by Alzheimer's Research UK (Org) in December 2025, dementia caused the deaths of 76,894 people in the UK, accounting for 11.8% of all deaths in the country, placing it as the first and foremost cause of death in the country. It is also observed that the number of deaths because of dementia increased from 75,393 deaths and 74,261 deaths to 76,894 deaths in the UK. Moreover, it is also estimated that according to statistics, there will be more than 1.4 million people suffering from dementia in the UK in 2040. This rising disease burden is expected to accelerate demand for APOE genotype testing and risk assessment.
The Global APOE Genotype Test market is segmented on the basis of Sample Type, Application, Offering, End User, and Region.
In the APOE Genotype Test market, blood sample genotype tests represent a key type segment since they are widely used for the precise determination of the APOE genotype and genetic risk and play the most essential role in clinical practice and scientific research. For example, in June 2026, as was stated by the World Health Organization (WHO), as many as 120.4 million blood donations will have been made worldwide by June 2026, and 36% of all blood donations (which account for only 15% of the whole population) will have come from high-income countries. The rate of donation of blood is also higher in high-income countries, being equal to 28.9 donations per 1,000 people compared to 18.2, 8.5, and 4.5 in upper-middle, lower-middle, and low-income economies, respectively.
APOE Genotype Test Market- Geographical Insights
North America is the most significant contributor to the global APOE Genotype Test market. There is high adoption of APOE genotyping technology in this region because of the advanced healthcare infrastructure, awareness levels of genetic tests, increasing prevalence of Alzheimer's disease, and the presence of laboratories and companies that carry out genetic testing. For instance, in June 2025, according to UT Southwestern Medical Center (org.), the usage of genetic tests in the US has recorded almost doubling from 19% to 40%. This shows that there has been an increase in adoption of genetic testing by consumers and positive growth prospects for the firms engaged in manufacturing and selling these tests. The consumers that have used the genetic tests have done so because of ancestry tests.
As per the report released on the issue, the DTC genetic testing market offers various types of ancestry tests, health risks, and a variety of other genetic tests that consumers can choose to undergo. DTC ancestry testing is available online as well as through physical stores, with costs ranging between less than $50 and $2,000, depending upon the type of test. This rising adoption is expected to create favorable opportunities for APOE genotype testing providers.
The competitive landscape features prominent companies such as 23andMe, LabCorp, Quest Diagnostics, Myriad Genetics, and Invitae Corporation. All these companies have a number of differences with regard to their positioning, diversification, use of technology, and other things. In April 2025, Quest Diagnostics came up with a new blood test for assessing the risk of Alzheimer's disease called the AD-Detect(TM) AB42/40 and p-tau217 Evaluation. Here, ApoE was used as a genetic risk marker, and there has been an improvement in the level of accuracy as well as a reduction in the percentage of people falling in the category of uncertain risk to 10%. These developments underscore the growing role of advanced genetic testing in Alzheimer's disease risk assessment.
In December 2025, Blueprint Genetics launched its APOE Single Gene Test, which is a specialized genetic test that analyzes the APOE gene for dysbetalipoproteinemia and lipoprotein glomerulopathy.